SRR1313162
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.450
- INTERFERON_ALPHA_RESPONSE+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- G2M_CHECKPOINT+0.360
- CHOLESTEROL_HOMEOSTASIS+0.350
- INTERFERON_GAMMA_RESPONSE+0.340
- ALLOGRAFT_REJECTION+0.320
- MTORC1_SIGNALING+0.310
- OXIDATIVE_PHOSPHORYLATION+0.300
- DNA_REPAIR+0.290
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- TGF_BETA_SIGNALING-0.490
- NOTCH_SIGNALING-0.480
- HEDGEHOG_SIGNALING-0.460
- WNT_BETA_CATENIN_SIGNALING-0.460
- ESTROGEN_RESPONSE_EARLY-0.420
- UV_RESPONSE_DN-0.400
- MYOGENESIS-0.350
- ANGIOGENESIS-0.340
- COAGULATION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320066 | — | — | 0.886 |
| 2 | TCGA-BB-A6UM-01A-12R-A34R-07 | — | — | 0.871 |
| 3 | c94686d5.355c.432f.bc98.ccdd30a209de | — | cohortA4 | 0.867 |
| 4 | TCGA-UY-A78K-01A-11R-A33J-07 | — | — | 0.823 |
| 5 | SRR12202422 | — | — | 0.822 |
| 6 | GSM6454730 | — | D | 0.821 |
| 7 | TCGA-AR-A0TV-01A-21R-A084-07 | — | B | 0.817 |
| 8 | TCGA-05-4397-01A-01R-1206-07 | — | cohortA4 | 0.813 |
| 9 | MNG85 | — | — | 0.812 |
| 10 | TCGA-BH-A0EE-01A-11R-A034-07 | — | C | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.020 | Inavolisib | — uncovered |